Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Original Research
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 16,315 | Dovepress* | 12,198+ | 1,862 | 14,060 | |
| PubMed Central* | 4,117 | 1,041 | 5,158 | ||
| Totals | 16,315 | 2,903 | 19,218 | ||
| *Since 13 February 2017 | |||||
View citations on PubMed and Google Scholar